Hey, folks, Scott Weingard here, and this is an M-Crit podcast. Today on the podcast, I am joined by my

partner in crime and buddy Josh Farkas. And we initially discussed the three big papers that came

out of the European Society of Intensive Care Medicine. That would be Endromeda Shock 2, Bicar

ICU 2, and Everdack. And it was a long conversation. So I am breaking

it up. So this one will be translating the recent sepsis literature to the bedside with a predominance

of the conversation focusing on translating Andromeda Shock 2. This will be the cap on all the

AS2 episodes that have come out recently. And then I will release as a separate episode our discussion

of Bicar ICU2 and Everdack. This one will be free for a while to the populace at large, but that

second episode on Bicar ICU2 and Everdack will be for members only. So if you like

this one, if you like hearing from Josh and I, then you should certainly subscribe as an

MCRIP member before that next episode comes out. This was a fantastic conversation. I think it puts

into context what you should actually be doing with all this new

recent sepsis literature. I think you're really going to enjoy it. Before we go to that,

just very quickly, here's the place I'm going to be speaking at in early 2006. I'm going to be

doing the awake and aware conference. That's one that I run with my buddies. And it's going to be

fracken. Amazing. It's Scottsdale,

Arizona. You should come March 2026. There is the HITS conference where I'm keynoting. That's health and

innovation technology symposium. That is going to be outside of San Diego, the Tamacula wine country,

super pretty. So that'll be in February.

And then, of course, incrementum, 2026, the second iteration of incrementum will be fantastic.

Already looking better than the first one, and the first one was insane. All right, let's get into the show. Josh and I talking about translating the current sepsis literature. So you need no introduction. Anyone who listens to M-Krit who doesn't know who you are, then we've had a problem in the dissemination pipe. But I'm joined by Josh Farkas, aka PalmCrit. How are you, Josh? I'm good.

Are you? Excellent. And today we're going to be discussing Entrometer Shock 2. We're going to be discussing Bicar ICU 2 and Everdak. Not from the perspective of an evidence-based analysis, though certainly you're not precluded from that, but really to translate this stuff to the bedside and what we should be doing. Absolutely. All right. So why do you give us your general gestalt and you've been assiduously working on translating this to the IBCC? So where do we stand? I'm really excited about this trial. I think we've gone stagnated in a way in our therapy of septic shock. For the average patient with septic shock, who I see admitted to my ICU, what happens is they come in, they get some fluid, they get some more epi, maybe they get a little baso, and that's it. Like, they're just parked in the corner. Someone checks the lactate, and most of the time they do fine. But I do think that this trial is hopefully an impetus to say, I think we could be doing

...